Tavares, D.C., Munari, C.C., Araujo, M.G., Beltrame, M.C., Fur-tado, M.H., Goncalves, C.C., Tiossi, R.F., Bastos, J.K., Cunha, W.R. and Veneziani, R.C. (2011) Antimutagenic potential of Solanum lycocarpum against induction of chromosomal aberrations in V79 and micronuclei in mice by doxorubicin. Planta Medica, 77, 1489-1494. doi:10.1055/s-0030-1270886

has been cited by the following article:

• TITLE: Drug therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents

  AUTHORS: Bill E. Cham

  KEYWORDS: Cancer; Skin Cancer; Solamargine; Solasonine; BEC; Solasodine Rhamnosyl Glycosides; CuradermBEC5; Apoptosis; Antineoplastic; Targeted Therapy

  JOURNAL NAME: Modern Chemotherapy, Vol.2 No.2, April 29, 2013

  ABSTRACT: In the last century, the discovery of cytotoxic agents was revolutionary for anticancer therapy. These therapies have resulted in better understanding of cancer in general. However, the development of agents that combine efficacy, safety and convenience remains a great challenge. The narrow, if not adverse, therapeutic index of most drugs, the damage not only to cancer cells, but also to normal and healthy tissue and the occurrence of resistance have limited anticancer efficacy. This review presents the development of promising novel cytotoxic solasodine rhamnosyl glycoside drugs that offer not only gains in specificity and efficacy, but also in safety, tolerability, non-resistance and convenience in the treatment of patients with cancer.